(MENAFN- Nxtgen Reports) In this report, the global consumption of varicella attenuated live vaccine products rises up from 34.99million doses in 2012 to 39.81 million doses in 2016, with an average annual growth rate of 3.44 %. At the same time, the revenue of world varicella attenuated live vaccine market has a leap from 1154.37 million dollars to 1515.52 million dollars. The reason causes this increase is the growing demand for the varicella attenuated live vaccine products, which is the outcome of the downstream industries are in a good situation.
A live attenuated varicella vaccine, derived from the Oka strain of VZV has clinical efficacy for the prevention of varicella.
The classification of consumption of varicella attenuated live vaccine includes Monovalent Vaccine and Combination Vaccine, and the revenue proportion of Monovalent Vaccine in 2016 was about 94.4%.
The downstream industries of varicella attenuated live vaccine products are kids and adults. In the recent years, with the recovery of global economic, the development of emerging countries and the rising health concern, the consumption increase of varicella attenuated live vaccine will be obvious. In the foreseeable future, the varicella attenuated live vaccine products will show an optimistic upward trend.
As for the global varicella attenuated live vaccine industry, the industry structure is relatively concentrated. 60.07% of market share in sales was grasped by Merck and GSK. The United States giant Merck, which had 48.70% market share in 2016, was the leader in the varicella attenuated live vaccine industry. The manufacturers following Merck are GSK and BCHT, which respectively had 11.3% and 10.8% market share globally. The BCHT was the leader of China varicella attenuated live vaccine industry. It sold a total of 76.26 million dollars in the year of 2016.
Geographically, this report split global into several key Regions, with sales (K Units), revenue (M USD), market share and growth rate of Varicella Attenuated Live Vaccine for these regions, from 2014 to 2026 (forecast), covering
China
USA
Europe
Japan
Korea
India
Southeast Asia
South America
Global Varicella Attenuated Live Vaccine market competition by top manufacturers/players, with Varicella Attenuated Live Vaccine sales volume, Price (USD/Unit), revenue (M USD) and market share for each manufacturer/player; the top players including
Company Name
Website
Company Type
Company Profile
Employees or Revenue
Products and Services
Established Date
Market Position or History
Contact Information
On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into
Monovalent Vaccine
Combination Vaccine
On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate of Varicella Attenuated Live Vaccine for each application, including
Kids Injection
Adults Injection
If you have any special requirements, please let us know and we will offer you the report as you want.
MENAFN26052023004360009250ID1106324814
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.